Contact

Click here for a confidential contact or call:

1-212-350-2764

January 22, 2019

Posted  January 23, 2019

Walgreens Boots Alliance, Inc. will pay $209.2 million to settle a False Claims Act case brought by two whistleblowers alleging that the retail pharmacy chain knowingly dispensed insulin pens to patients who did not need them, and billed Medicare, Medicaid, and other government insurance programs for those unnecessary items.  As part of the settlement, Walgreens admitted that it prevented pharmacists from dispensing fewer than five insulin pens at a time and altered records regarding dispensing information and days-of-supply so that patients received more insulin pens than they actually needed.  $168 million of the settlement will be paid to the U.S., and approximately $41.2 million to state governments. The whistleblowers, Adam Rahimi and S. Christopher Schulte, will receive a share of the total settlement, to be determined at a later date.  USAO SDNY.  See also, NY, OH

Tagged in: Dosage Fraud, FCA Federal, FCA State, Pharma Fraud, Whistleblower Case, Whistleblower Rewards,

Newsletter

Subscribe to receive email updates from the Constantine Cannon blogs

Sign up for: